• Xolatryp Phase I clinical trial completed with strong safety profile
• Phase IIa clinical trial planned to assess safety and efficacy in STEMI patients
• Successful AU$8.25 million capital raise to fund Phase IIa trial and R&D

Nyrada Inc. (ASX:NYR), a clinical-stage biotechnology company, has announced its Quarterly Activities Report and Appendix 4C for the three months ending 30 September 2025. The key highlights include:Xolatryp Program:- Phase I clinical trial completed with a strong safety profile confirmed, no serious adverse events, and predictable, linear pharmacokinetics observed.- Phase IIa clinical trial planned to assess safety and explore efficacy of Xolatryp in STEMI patients undergoing PCI, addressing a critical unmet need in ischemia-reperfusion injury.- HREC submission for Phase IIa trial expected to be lodged in 2QFY2026 with patient dosing expected to commence in 3QFY2026.- Collaboration with WRAIR and UNSW Sydney confirmed Xolatryp reduces mitochondrial calcium loading in the brain, reinforcing its mechanism of action in cardiac and brain injury protection.Finance and Capital:- Sound financial position with a cash balance of AU$7.92 million at 30 September 2025.- Successful capital raise secured AU$8.25 million (before costs) in August 2025 via placement to institutional and professional investors, funding upcoming Phase IIa trial and R&D initiatives.Corporate:- Annual General Meeting scheduled for 12 November 2025, with both in-person (Sydney) and online participation.- Board transition with the appointment of CEO James Bonnar to the board and the retirement of Gisela Mautner.